Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After ...

Shares of Gilead Sciences Inc. GILD slid 2.81% to $103.17 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.74% to 5,525.21 and ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Short interest in Gilead Sciences Inc (NASDAQ:GILD) decreased during the last reporting period, falling from 22.34M to 21.39M. This put 1.72% of the company's publicly available shares short.